Citations

Clear

86 citation(s) found for "Frank, Ryan".

Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome*
Festić, Emir , Carr, Gordon, Cartin‐Ceba, Rodrigo , Hinds, Richard , Banner‐Goodspeed, Valerie , Bansal, Vikas , Asuni, Adijat T., Talmor, Daniel , Rajagopalan, Govindarajan, Frank, Ryan D. , Matthay, Michael A. , Levitt, Joseph E. , Asuni, Adijat, Gajic, Ognjen , Bansal, Vikas

Mayo Clinic

Critical Care Medicine | February 25, 2017 | Volume: 45 | Issue: 5 | Pages: 798-805

10.1097/ccm.0000000000002284 | PMID 28240689 Get It

Objectives: Effective pharmacologic treatments directly targeting lung injury in patients with the acute respiratory distress syndrome are lacking. Early treatment with inhaled corticosteroids and beta agonists may reduce progression to acute respiratory distress syndrome by reducing lung inflammation and enhancing alveolar fluid clearance. Design: Double-blind, randomized clinical trial (ClinicalTrials.gov: NCT01783821). The primary outcome was longitudinal change in oxygen saturation divided by the F io 2 (S/F) through day 5. We also analyzed categorical change in S/F by greater than 20%. Other outcomes included need for mechanical ventilation and development of acute respiratory distress syndrome. Setting: Five academic centers in the United States. Patients: Adult patients admitted through the emergency department at risk for acute respiratory distress syndrome. Interventions: Aerosolized budesonide/formoterol versus placebo bid for up to 5 days. Measurements and Main Results: Sixty-one patients were enrolled from September 3, 2013, to June 9, 2015. Median time from presentation to first study drug was less than 9 hours. More patients in the control group had shock at enrollment (14 vs 3 patients). The longitudinal increase in S/F was greater in the treatment group ( p = 0.02) and independent of shock ( p = 0.04). Categorical change in S/F improved ( p = 0.01) but not after adjustment for shock ( p = 0.15). More patients in the placebo group developed acute respiratory distress syndrome (7 vs 0) and required mechanical ventilation (53% vs 21%). Conclusions: Early treatment with inhaled budesonide/formoterol in patients at risk for acute respiratory distress syndrome is feasible and improved oxygenation as assessed by S/F. These results support further study to test the efficacy of inhaled corticosteroids and beta agonists for prevention of acute respiratory distress syndrome.
A new model for predicting breast cancer risk in women with atypical hyperplasia.
Dupont, William D. , Frank, Ryan D. , Frost, Marlene H., Vachon, Celine M, Ghosh, Karthik , Haddad, Tufia C. , Denison, Lori A., Visscher, Daniel W., Hartmann, Lynn C. , Degnim, Amy C. , Pankratz, V. Shane , Winham, Stacey J. , Vierkant, Robert A. , Hieken, Tina J. , Carter, Jodi M. , Radisky, Derek C.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 28_suppl | Pages: 2-2

10.1200/jco.2015.33.28_suppl.2 Get It

2 Background: Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but accurate personalized risk prediction is desirable to facilitate individual clinical management decisions. Currently used models provide poor BC risk prediction for women with AH. Our goal was to develop and validate an improved risk prediction model for women with AH. Methods: From a cohort of 13,538 women with benign breast disease from 1967-2001, pathology review confirmed 699 with AH. Clinical risk factors and histologic features of the tissue biopsy were recorded, and BC events were ascertained from study questionnaires, tumor registry, and review of medical records. Using a lasso approach, 23 variables were assessed for model inclusion. Lasso-identified features were then fit in a Cox regression model to estimate BC risk. Model discrimination was assessed with C-statistics in the model-building set and in a separate external validation set. Calibration was assessed by comparing observed to predicted breast cancer counts. Results: The model-building set comprised 699 women with 142 BC events (median follow-up 8.1 years), and the external validation set comprised 461 women with 114 BC events (median follow-up 11.4 years). The final model included three covariates: age at biopsy, age squared, and number of foci of AH. Model performance was good, with a C-statistic of 0.622 (SE = 0.027) in the model-building set and 0.594 (SE = 0.029) in the external validation set. The model is well-calibrated, with observed to expected numbers of BCs nearly equal across all post-biopsy follow-up years. Conclusions: We propose a new model for predicting BC risk in women with AH based on age at biopsy and number of foci of atypia. This model provides absolute risk estimates for women with AH, has good discriminatory ability, is well-calibrated, and validates in an external cohort.
Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.
Anderson, S. Keith , Oberg, Ann L. , Frank, Ryan D. , Frost, Marlene H., Visscher, Daniel W., Radisky, Derek C. , Degnim, Amy C. , Nassar, Aziza , Stallings‐Mann, Melody , Winham, Stacey J. , Vierkant, Robert A. , Wang, Chen

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 28_suppl | Pages: 18-18

10.1200/jco.2015.33.28_suppl.18 Get It

18 Background: Benign breast disease (BBD) is diagnosed in 1-2 million women/year in the US, and while these patients are known to be at substantially increased risk for subsequent development of breast cancer, existing models for risk assessment perform poorly at the individual level. Here, we describe a DNA-microarray-based transcriptional model for breast cancer risk prediction for patients with sclerosing adenosis (SA), a lesion found in ¼ of all BBD patients that is characterized by epithelial proliferation, disordered acinar architecture, and stromal fibrosis. Methods: A training set was developed from 86 patients diagnosed with sclerosing adenosis (SA), of which 27 subsequently developed cancer within 10 years (cases) and 59 remained cancer-free at 10 years (controls). A diagonal linear discriminate analysis (DLDA)-prediction model for prediction of cancer within 10 years (SA TTC10) was generated from transcriptional profiles of formalin fixed, paraffin-embedded (FFPE) biopsy-derived RNA. This model was tested on a separate validation case-control set composed of 65 SA patients. Results: The SA TTC10 gene signature model, composed of 35 gene features, achieved a clear and significant separation between case and control with receiver operating characteristic area under the curve of 0.913 in the training set and 0.836 in the validation set. Conclusions: Our results provide the first demonstration that benign breast tissue contains transcriptional alterations that indicate risk of breast cancer development, and that essential precursor biomarkers of malignancy are present many years prior to cancer development. Furthermore, the SA TTC10 gene signature model, which can be assessed on FFPE biopsies, constitutes a novel prognostic biomarker for patients with SA.
Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies
Visscher, Daniel W., Frank, Ryan D. , Carter, Jodi M. , Vierkant, Robert A. , Heinzen, Ethan P. , Broderick, Brendan T., Denison, Lori A., Allers, Teresa M., Johnson, Joanne L., Frost, Marlene H., Hartmann, Lynn C. , Winham, Stacey J. , Radisky, Derek C. , Degnim, Amy C. , Vierkant, Robert A , Carter, Jodi

Mayo Clinic

JNCI: Journal of the National Cancer Institute | February 16, 2017 | Volume: 109 | Issue: 10 | Pages: No page available

10.1093/jnci/djx035 | PMID 28376198 Get It

Has Sliding-Clip Renorrhaphy Eliminated the Need for Collecting System Repair During Robot-Assisted Partial Nephrectomy?
Williams, Robert D. , Snowden, Caroline, Frank, Ryan D. , Thiel, David D. , Frank, Ryan

Mayo Clinic

Journal of Endourology | December 13, 2016 | Volume: 31 | Issue: 3 | Pages: 289-294

10.1089/end.2016.0562 | PMID 27960537 Get It

Objective: We evaluated whether single-layer renorrhaphy (SLR) without collecting system (CS) closure is sufficient following robot-assisted partial nephrectomy (RAPN). Patients and Methods: One hundred fifty consecutive patients underwent RAPN by a single surgeon and were prospectively labeled with regard to CS entry during surgery. Patients with CS entry were subdivided into two groups: those with classical renorrhaphy (CR) (i.e., two-layer repair) and those with SLR (i.e., without CS repair). Perioperative variables and outcomes were compared between CR and SLR groups. Results: Ninety patients had CS entry during RAPN. Of these 90 patients, 64 had CR, and 26 had SLR, with mean ages of 62 and 59 years ( p = 0.22), tumor sizes of 3.4 and 3.3 cm ( p = 0.61), Mayo Adhesive Probability scores of 1.8 and 1.8 ( p = 0.95), and radius, exophytic/endophytic, nearness to CS, and laterality scores of 8.5 and 8.0 ( p = 0.16), respectively. Mean warm ischemia times (WITs) were 19.6 and 17.3 minutes ( p = 0.04), hospital stays of 3.0 and 2.8 days ( p = 0.62), and drain times of 2.9 and 2.7 days ( p = 0.65), for the CR and SLR groups, respectively. Using the Clavien-Dindo classification, there were a total of six grade III or higher complications, with no difference between the CR and SLR subgroups ( p = 1.0). Renal function using creatinine or glomerular filtration rate as surrogates showed no difference between groups preoperatively or up until 2 years postoperatively. Conclusions: Omitting CS repair during RAPN with SLR decreases WIT without altering complications, hospital stay, or drain time. Long-term renal function was not associated with CS repair.
Abstract LB-364: Natural history of age-related lobular involution and impact on breast cancer risk
Visscher, Daniel W., Frank, Ryan D. , Vachon, Celine M. , Denison, Lori A., Hartmann, Lynn C. , Frost, Marlene H., Radisky, Derek C. , Vierkant, Robert A. , Winham, Stacey J. , Stallings‐Mann, Melody , Hoskin, Tanya L. , Nassar, Aziza , Vachon, Celine M. , Degnim, Amy C.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: LB-364-LB-364

10.1158/1538-7445.am2016-lb-364 Get It

Abstract Background: Age-related lobular involution (LI) is a physiological process in which the terminal duct lobular units of the breast regress as a woman ages. Analyses of breast biopsies from women with benign breast disease (BBD) have found that extent of LI is negatively associated with subsequent breast cancer development. Here we assess the natural course of LI within individual women, and the impact of progressive LI on breast cancer risk. Methods: The Mayo Clinic BBD cohort consists of 13,455 women with BBD from 1967-2001. The BBD cohort includes 1115 women who had multiple benign biopsies, 106 of whom had developed breast cancer. Within this multiple biopsy cohort, the progression of the LI process was examined by age at initial biopsy and time between biopsies. The relationship between LI progression and breast cancer risk was assessed using standardized incidence ratios (SIRs) and by Cox proportional hazards analysis. Results: Women who had multiple biopsies were younger age and had a slightly higher family history of breast cancer as compared with the overall BBD cohort. Extent of LI at subsequent biopsy was greater with increasing time between biopsies and for women age 55+ at initial biopsy. Among women with multiple biopsies, there was a significant association of higher breast cancer risk among those with involution stasis (lack of progression, HR 1.63) as compared with those with involution progression, p = 0.036. Conclusions: The multiple biopsy BBD cohort allows for a longitudinal study of the natural progression of LI. The majority of women in the multiple biopsy cohort showed progression of LI status between benign biopsies, and extent of progression was highest for women who were in the perimenopausal age range at initial biopsy. Progression of LI status between initial and subsequent biopsy was associated with decreased breast cancer risk. Citation Format: Derek Radisky, Daniel W. Visscher, Ryan Frank, Robert A. Vierkant, Stacey J. Winham, Melody L. Stallings-Mann, Tanya L. Hoskin, Aziza Nassar, Celine M. Vachon, Lori A. Denison, Lynn C. Hartmann, Marlene H. Frost, Amy C. Degnim. Natural history of age-related lobular involution and impact on breast cancer risk. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-364.
Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women
Dupont, William D. , Vierkant, Robert A. , Frank, Ryan D. , Frost, Marlene H., Winham, Stacey J. , Smith, Jeffrey R. , Page, David L., Vachon, Celine M. , Ghosh, Karthik, Denison, Lori A., Carter, Jodi M. , Hartmann, Lynn C. , Visscher, Daniel W., Radisky, Derek C. , Hoskin, Tanya L. , Degnim, Amy C. , Sanders, Melinda E. , Vachon, Celine M. , Hieken, Tina J. , Winham, Stacey J , Vierkant, Robert A , Carter, Jodi

Mayo Clinic

Cancer | June 29, 2016 | Volume: 122 | Issue: 19 | Pages: 2971-2978

10.1002/cncr.30153 | PMID 27352219 Get It

BACKGROUNDWomen with atypical hyperplasia (AH) on breast biopsy have a substantially increased risk of breast cancer (BC). Here the BC risk for the extent and subtype of AH is reported for 2 separate cohorts.METHODSAll samples containing AH were included from 2 cohorts of women with benign breast disease (Mayo Clinic and Nashville). Histology review quantified the number of foci of atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). The BC risk was stratified for the number of AH foci within AH subtypes.RESULTSThe study included 708 Mayo AH subjects and 466 Nashville AH subjects. In the Mayo cohort, an increasing number of foci of AH was associated with a significant increase in the risk of BC both for ADH (relative risks of 2.61, 5.21, and 6.36 for 1, 2, and ≥3 foci, respectively; P for linear trend = .006) and for ALH (relative risks of 2.56, 3.50, and 6.79 for 1, 2, and ≥3 foci, respectively; P for linear trend = .001). In the Nashville cohort, the relative risks of BC for ADH were 2.70, 5.17, and 15.06 for 1, 2, and ≥3 foci, respectively (P for linear trend < .001); for ALH, the relative risks also increased but not significantly (2.61, 3.48, and 4.02, respectively; P = .148). When the Mayo and Nashville samples were combined, the risk increased significantly for 1, 2, and ≥3 foci: the relative risks were 2.65, 5.19, and 8.94, respectively, for ADH (P < .001) and 2.58, 3.49, and 4.97, respectively, for ALH (P = .001).CONCLUSIONSIn 2 independent cohort studies of benign breast disease, the extent of atypia stratified the long‐term BC risk for ADH and ALH. Cancer 2016;122:2971‐2978. © 2016 American Cancer Society.
Breast cancer risk by the extent and type of atypical hyperplasia
Visscher, Daniel W., Frost, Marlene H., Vierkant, Robert A. , Frank, Ryan D. , Winham, Stacey J. , Vachon, Celine M. , Dupont, William D. , Hartmann, Lynn C. , Radisky, Derek C. , Degnim, Amy C. , Vachon, Celine M. , Winham, Stacey J , Vierkant, Robert A

Mayo Clinic

Cancer | June 28, 2016 | Volume: 122 | Issue: 19 | Pages: 3087-3088

10.1002/cncr.30151 | PMID 27352099 Get It

Clinicopathologic features of breast cancers that develop in women with previous benign breast disease
Visscher, Daniel W., Frost, Marlene H., Hartmann, Lynn C. , Frank, Ryan D. , Vierkant, Robert A. , McCullough, Ann E. , Winham, Stacey J. , Vachon, Celine M. , Ghosh, Karthik, Brandt, Kathleen R. , Farrell, Ann , Tarabishy, Yaman, Haddad, Tufia C. , Kraft, Ruth, Farrell, Ann M, Kraft, Ruth A, Radisky, Derek C. , Vachon, Celine M. , Hieken, Tina J. , Degnim, Amy C. , Winham, Stacey J , Vierkant, Robert A

Mayo Clinic

Cancer | October 29, 2015 | Volume: 122 | Issue: 3 | Pages: 378-385

10.1002/cncr.29766 | PMID 26512815 Get It

BACKGROUNDWomen with benign breast disease (BBD) have an increased risk of developing breast cancer (BC). Nearly 30% of all BCs develop in women with prior BBD. Information regarding features of the expected number of BCs after BBD would enhance individualized surveillance and prevention strategies for these women. In the current study, the authors sought to characterize BCs developing in a large cohort of women with BBD.METHODSThe current study cohort included 13,485 women who underwent breast biopsy for mammographic or palpable concerns between 1967 and 2001. Biopsy slides were reviewed and classified as nonproliferative disease, proliferative disease without atypia, or atypical hyperplasia. BCs were identified by follow‐up questionnaires, medical records, and Tumor Registry data. BC tissues were obtained and reviewed.RESULTSWith median follow‐up of 15.8 years, 1273 women developed BC. The majority of BCs were invasive (81%), of which 61% were ductal, 13% were mixed ductal/lobular, and 14% were lobular. Approximately two‐thirds of the BC cases were intermediate or high grade, and 29% were lymph node positive. Cancer characteristics were similar across the 3 histologic categories of BBD, with a similar frequency of ductal carcinoma in situ, invasive disease, tumor size, time to invasive BC, histologic type of BC, lymph node positivity, and human epidermal growth factor receptor 2 positivity. Women with atypical hyperplasia were found to have a higher frequency of estrogen receptor‐positive BC (91%) compared with women with proliferative disease without atypia (80%) or nonproliferative disease (85%) (P = .02).CONCLUSIONSA substantial percentage of all BCs develop in women with prior BBD. The majority of BCs after BBD are invasive tumors of ductal type, with a substantial number demonstrating lymph node positivity. Of all the BCs in the current study, 84% were estrogen receptor positive. Prevention therapy should be strongly encouraged in higher‐risk women with BBD. Cancer 2016;122:378–385. © 2015 American Cancer Society.
Reply to M.H. Gail et al
Pankratz, V. Shane , Vierkant, Robert A. , Frank, Ryan D. , Hartmann, Lynn C., Degnim, Amy C. , Vierkant, Robert A

Mayo Clinic

Journal of Clinical Oncology | July 28, 2015 | Volume: 33 | Issue: 25 | Pages: 2830-2831

10.1200/jco.2015.62.5756 | PMID 26215951 Get It